Emerging therapies under investigation for ovarian cancer include antibody-drug conjugates (ADCs) targeting folate receptor alpha (FRα) [8], anti-angiogenesis drugs, PI3K/AKT/mTOR signaling pathway inhibitors [9], recombinant arazyme [10], and targeting Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) [11]. This evidence concerns the gene FOLR1 and ovarian carcinoma.